AQILION AB (publ) is presenting preclinical data in the Alnitak program for the first time at the conference BIO-Europe 2021. The Alnitak program focuses on inhibition of the TAK1 target protein. By…
Helsingborg, Sweden – June 18, 2021 – AQILION AB (publ) held its Annual General Meeting today on June 18, 2021, during which the Meeting resolved in accordance with the proposals set forth by the…
AQILION AB (publ) announces hereby that the Swedish version of the 2020 Annual Report has been published and is available on the company’s website. The 2020 Annual Report in Swedish can be…
Aqilion announced today that the company has initiated an expanded collaborative effort with Professor Eva Särndahl and Senior Lecturer Alexander Persson at the School of Medical Sciences, Örebro…
Aqilion announced today that Johan Lund, the current Chairman of the company, will join the operational team as Chief Scientific Officer beginning on March 1. Johan Lund will mainly contribute his…